Effectiveness of ivermectin mass drug administration in the control of soil-transmitted helminth infections in endemic populations: a systematic review and meta-analysis

作     者：Brandon Le Naomi E.Clarke Nicolas Legrand Susana Vaz Nery Brandon Le;Naomi E. Clarke;Nicolas Legrand;Susana Vaz Nery

作者机构：The Kirby InstituteUniversity of New South WalesLevel 6Wallace Wurth BuildingSydneyNSW2052Australia 

出 版 物：《Infectious Diseases of Poverty》 (贫困所致传染病（英文）)

年 卷 期：2024年第13卷第1期

页      面：1-15页

核心收录：

学科分类：0401[教育学-教育学] 1004[医学-公共卫生与预防医学(可授医学、理学学位)] 04[教育学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 

基　　金：SVN is funded by a NHMRC Investigator Grant.The corresponding author (BL) and senior authors (NEC and SVN) had full access to all the data and had final responsibility for the decision to submit for publication 

主　　题：Soil-transmitted helminths Ivermectin Albendazole Mass drug administration Preventive chemotherapy 

摘      要：Background Current soil-transmitted helminth(STH)control guidelines endorse the use of albendazole or meben-dazole for school-based targeted preventive chemotherapy(PC),yet their reduced efficacy against Strongyloides sterc-oralis and Trichuris trichiura presents significant *** evidence indicates that community-wide PC[or mass drug administration(MDA)]using ivermectin,commonly used in other neglected tropical disease(NTD)control programs,may play an important role in controlling these *** conducted a systematic review and meta-analysis to evaluate the effectiveness of ivermectin PC in reducing STH prevalence in endemic *** We searched Pubmed,EMBASE,and Web of Science on February 14,2023,for studies that investigated the effectiveness of ivermectin PC,either alone or in combination with other anthelmintic drugs,on STH infec-tions,and provided a measure of STH prevalence before and after *** calculated pooled prevalence reductions for each STH using random-effects *** protocol is available on PROSPERO(registration number CRD42023401219).Results A total of 21 were eligible for the systematic review,of which 15 were eligible for *** studies delivered ivermectin through *** pooled prevalence reduction of *** following MDA with ivermec-tin alone was 84.49%(95%CI:54.96-94.66)across five studies and 81.37%(95% CI:61.62-90.96)across seven studies with or without *** prevalence reduction of *** was 49.93%(95%CI:18.23-69.34)across five studies with ivermectin alone,and 89.40%(95%CI:73.66-95.73)across three studies with the addition of *** was high heterogeneity for all syntheses(I^(2)65%).Conclusions This study underscores the key role of ivermectin-based MDA in addressing limitations in current global STH guidelines in terms of limited efficacy against *** and *** on these findings,revising inter-national STH guidelines to include i